Table 1 Baseline characteristics of patients with Crohn's disease
From: The effect of biological agent on body composition in patients with Crohn’s disease
Characteristics | Total (n = 112) | Myopenia (n = 79) | Non-myopenia (n = 33) | P-value |
|---|---|---|---|---|
Age (years) | 35.5 (28.5–41.0) | 36.0 (29.0–40.5) | 32.0 (27.0–41.0) | 0.293 |
Male sex | 82 (73.2%) | 68 (86.1%) | 14 (42.4%) | < 0.001 |
BMI (kg/m2) | 21.0 (18.5–23.7) | 20.6 (17.7–22.8) | 22.3 (20.1–24.5) | 0.010 |
Previous abdominal surgery | 48 (42.9%) | 34 (43.0%) | 14 (42.4%) | 1.000 |
Smoking habit | 17 (15.2%) | 15 (19.0%) | 2 (6.1%) | 0.147 |
Montreal classification | ||||
Age at diagnosis (years) | ||||
A2(18–40) | 91 (81.2%) | 65 (82.3%) | 26 (78.8%) | 0.868 |
A3(> 40) | 21 (18.8%) | 14 (17.7%) | 7 (21.2%) | 0.868 |
Location | ||||
L1(Ileum) | 20 (17.9%) | 12 (15.2%) | 8 (24.2%) | 0.384 |
L2(Colon) | 26 (23.2%) | 21 (26.6%) | 5 (15.2%) | 0.289 |
L3(Ileocolon) | 66 (58.9%) | 46 (58.2%) | 20 (60.6%) | 0.982 |
L4(Upper GI) | 18 (16.1%) | 12 (15.2%) | 6 (18.2%) | 0.912 |
Behavior | ||||
B1(Inflammatory) | 42 (37.5%) | 30 (38.0%) | 12 (36.4%) | 1.000 |
B2(Stricturing) | 49 (43.8%) | 33 (41.8%) | 16 (48.5%) | 0.657 |
B3(Penetrating) | 21 (18.8%) | 16 (20.3%) | 5 (15.2%) | 0.715 |
P(Perianal disease) | 70 (62.5%) | 49 (62.0%) | 21 (63.6%) | 1.000 |
Extra-intestinal manifestation | 44 (39.3%) | 30 (38.0%) | 14 (42.4%) | 0.820 |
Disease duration (years) | 10.9 (7.2–14.4) | 11.0 (7.6–14.6) | 9.2 (6.8–13.8) | 0.264 |
Biologics | ||||
Infliximab | 76 (67.9%) | 51 (64.6%) | 25 (75.8%) | 0.350 |
Adalimumab | 45 (40.2%) | 33 (41.8%) | 12 (36.4%) | 0.748 |
Ustekinumab | 6 (5.4%) | 4 (5.1%) | 2 (6.1%) | 1.000 |
Vedolizumab | 1 (0.9%) | 0 (0.0%) | 1 (3.0%) | 0.651 |
Refractory (2 or more biologics) | 13 (11.6%) | 7 (8.9%) | 6 (18.2%) | 0.280 |
Biologics treatment duration (months) | 64.0 (30.5–93.5) | 66.0 (32.0–97.5) | 58.0 (26.0–82.0) | 0.457 |
Operation after biologics | 21 (18.8%) | 18 (22.8%) | 3 (9.1%) | 0.154 |
Concurrent medical treatment | ||||
steroid | 25 (22.3%) | 16 (20.3%) | 9 (27.3%) | 0.572 |
5-ASA | 94 (83.9%) | 65 (82.3%) | 29 (87.9%) | 0.650 |
Azathioprine | 56 (50.0%) | 40 (50.6%) | 16 (48.5%) | 1.000 |